Estimating prognosis at the time of repeat whole brain radiation therapy for multiple brain metastases: The reirradiation score

• Published in: Advances in radiation oncology 2017-07, Vol.2 (3), p.381-390
• Main Authors: Logie, Natalie, MD, Jimenez, Rachel B., MD, Pulenzas, Natalie, BSc, Linden, Kelly, MRT (T), Ciafone, Denise, NP, Ghosh, Sunita, PhD, Xu, Yuhui, MSc, BSc, Lefresne, Shilo, MD, Wong, Erin, BSc, Son, Christina H., MD, Shih, Helen A., MD, MS, MPH, Wong, William W., MD, Tyldesley, Scott, MD, MPA, Dennis, Kristopher, MD, Chow, Edward, MBBS, MSc, PhD, Fairchild, Alysa M., MD
• Format: Article
• Language: English
• Subjects: Hematology, Oncology, and Palliative Medicine; Scientific
• ISSN: 2452-1094; 2452-1094
• DOI: 10.1016/j.adro.2017.05.010

Abstract Purpose Whole brain radiation therapy (WBRT) remains the standard of care for patients with multiple brain metastases, but more than half of treated patients will develop intracranial progression. Because there is no clear consensus on the optimal therapeutic approach, a prognostic index would be helpful to guide treatment options at progression. We explored whether the recursive partitioning analysis (RPA) score prior to repeat WBRT is predictive of survival. Methods and materials This multi-institutional pooled analysis included patients with 2 or more brain metastases from any solid primary tumor that was treated with 2 courses of WBRT. Information on demographics, disease characteristics, and intervals between courses was collected. RPA class was abstracted or retrospectively assigned, and descriptive statistics calculated. Median survival (MS) was determined using the Kaplan-Meier method and compared using log rank tests. Univariate and multivariate analyses were performed via Cox regression analysis. Results For 205 patients, the median age was 55 years (range, 25-83 years), 68% were female, 40.5% had non-small cell lung cancer, and 31.2% had small cell lung cancer. Prior to the second WBRT, 4.9% of patients were RPA class 1, 36.6% were RPA2, and 58.5% were RPA3, with an MS of 7.5 months (95% confidence interval [CI], 4.7-10.3), 5.2 months (95% CI, 3.7-6.7 months), and 2.9 months (95% CI, 2.2-2.9 months), respectively ( P = .001). On univariate and multivariate analyses, a Karnofsky Performance Status of